Teneo_logo_FINAL_whitebkgnd.png
Teneobio’s Clinical Candidate, TNB-409, is a Selective IL-2 Receptor Bispecific Agonist for the Treatment of Solid Tumors
19 mai 2021 08h00 HE | TeneoBio, Inc
NEWARK, Calif., May 19, 2021 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies,...